• Exchange: Stuttgart
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

NV9:GR

0.086 EUR 0.012 12.24%

As of 03:04:39 ET on 08/29/2014.

Snapshot for Novogen Ltd (NV9)

Open: 0.091 Day's Range: 0.086 - 0.098 Volume: 0
Previous Close: 0.098 52wk Range: 0.070 - 0.218 1-Yr Rtn: +7.50%

Stock Chart for NV9

No chart data available.
  • NV9:GR 0.086
  • 1D
  • 1M
  • 1Y
0.098
Interactive NV9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NV9

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. DAX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M EUR) 14.50
Shares Outstanding (M) 168.56
30 Day Average Volume 0
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/29/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NV9

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for NV9

Novogen Limited is a medical services company which develops and markets pharmaceutical products in Australia. The Company conducts clinical trials on medications which promote the prevention and treatment of common cancers and the reversal of immune depression. The Company also develops dietary supplements, hormonal imbalance drugs, anti-inflammatory and cardiovascular drugs.

Graham Edmund KellyChairman/CEO/FounderDavid BrownChief Scientific Officer
Justine StehnDir:ATM ProgramStephen PalmerDir:Degenerative Disease Program
More Company Profile & Key Executives for NV9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil